EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 33 / Numéro 5 (Mai 2017) Med Sci (Paris), 33 5 (2017) 499-505 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 33, Numéro 5, Mai 2017
Page(s) 499 - 505
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20173305013
Publié en ligne 14 juin 2017
  1. Nègre N, Cavalli G. Polycomb maîtrise la destinée cellulaire. Med/Sci (Paris) 2006 ; 22 : 1033–1035. [Google Scholar]
  2. Turner SA, Bracken AP. A “Complex” Issue: Deciphering the Role of Variant PRC1 in escs. Cell Stem Cell 2013 ; 12 : 145–146. [Google Scholar]
  3. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 2004 ; 15 : 57–67. [CrossRef] [PubMed] [Google Scholar]
  4. Shen X, Liu Y, Hsu Y-J, et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 2008 ; 32 : 491–502. [CrossRef] [PubMed] [Google Scholar]
  5. Vizán P, Beringer M, Ballaré C, et al. Role of PRC2-associated factors in stem cells and disease. FEBS J 2015 ; 282 : 1723–1735. [CrossRef] [PubMed] [Google Scholar]
  6. Simon J, Chiang A, Bender W, et al. Elements of the Drosophila bithorax complex that mediate repression by Polycomb group products. Dev Biol 1993 ; 158 : 131–144. [PubMed] [Google Scholar]
  7. Woo CJ, Kharchenko PV, Daheron L, et al. A region of the human HOXD cluster that confers polycomb-group responsiveness. Cell 2010 ; 140 : 99–110. [PubMed] [Google Scholar]
  8. Cuddapah S, Roh T-Y, Cui K, et al. A novel human polycomb binding site acts as a functional polycomb response element in Drosophila. Plos One 2012 ; 7 : e36365. [PubMed] [Google Scholar]
  9. Margueron R, Justin N, Ohno K, et al. Role of the polycomb protein Eed in the propagation of repressive histone marks. Nature 2009 ; 461 : 762–767. [CrossRef] [PubMed] [Google Scholar]
  10. Lee TI, Jenner RG, Boyer LA, et al. Control of developmental regulators by polycomb in human embryonic stem cells. Cell 2006 ; 125 : 301–313. [PubMed] [Google Scholar]
  11. Mendenhall EM, Koche RP, Truong T, et al. GC-rich sequence elements recruit PRC2 in mammalian ES cells. Plos Genet 2010 ; 6 : e1001244. [CrossRef] [PubMed] [Google Scholar]
  12. Morey L, Helin K. Polycomb group protein-mediated repression of transcription. Trends Biochem Sci 2010 ; 35 : 323–332. [CrossRef] [PubMed] [Google Scholar]
  13. Zhao J, Sun BK, Erwin JA, et al. Polycomb proteins targeted by a short repeat RNA to the mouse X-chromosome. Science 2008 ; 322 : 750–756. [Google Scholar]
  14. da Rocha ST, Boeva V, Escamilla-Del-Arenal M, et al. Jarid2 is implicated in the initial Xist-induced targeting of PRC2 to the inactive X chromosome. Mol Cell 2014 ; 53 : 301–316. [CrossRef] [PubMed] [Google Scholar]
  15. Kaneko S, Bonasio R, Saldaña-Meyer R, et al. Interactions between JARID2 and noncoding rnas regulate PRC2 recruitment to chromatin. Mol Cell 2014 ; 53 : 290–300. [CrossRef] [PubMed] [Google Scholar]
  16. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002 ; 298 : 1039–1043. [Google Scholar]
  17. Wang L, Brown JL, Cao R, et al. Hierarchical recruitment of polycomb group silencing complexes. Mol Cell 2004 ; 14 : 637–646. [CrossRef] [PubMed] [Google Scholar]
  18. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006 ; 6 : 846–856. [Google Scholar]
  19. Blackledge NP, Farcas AM, Kondo T, et al. Variant PRC1 complex-dependent H2A ubiquitylation drives PRC2 recruitment and polycomb domain formation. Cell 2014 ; 157 : 1445–1459. [PubMed] [Google Scholar]
  20. Cooper S, Dienstbier M, Hassan R, et al. Targeting polycomb to pericentric heterochromatin in embryonic stem cells reveals a role for H2AK119u1 in PRC2 Recruitment. Cell Rep 2014 ; 7 : 1456–1470. [CrossRef] [PubMed] [Google Scholar]
  21. Kalb R, Latwiel S, Baymaz HI, et al. Histone H2A monoubiquitination promotes histone H3 methylation in Polycomb repression. Nat Struct Mol Biol 2014 ; 21 : 569–571. [CrossRef] [PubMed] [Google Scholar]
  22. Kim E, Kim M, Woo D-H, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 2013 ; 23 : 839–852. [CrossRef] [PubMed] [Google Scholar]
  23. Lee JM, Lee JS, Kim H, et al. EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Mol Cell 2012 ; 48 : 572–586. [CrossRef] [PubMed] [Google Scholar]
  24. Sanulli S, Justin N, Teissandier A, et al. Jarid2 methylation via the PRC2 complex regulates h3k27me3 deposition during cell differentiation. Mol Cell 2015 ; 57 : 769–783. [CrossRef] [PubMed] [Google Scholar]
  25. Shi B, Liang J, Yang X, et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol 2007 ; 27 : 5105–5119. [CrossRef] [PubMed] [Google Scholar]
  26. Li X, Gonzalez ME, Toy K, et al. Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. Am J Pathol 2009 ; 175 : 1246–1254. [PubMed] [Google Scholar]
  27. Lee ST, Li Z, Wu Z, et al. Context-specific regulation of NF-κb target gene expression by EZH2 in breast cancers. Mol Cell 2011 ; 43 : 798–810. [CrossRef] [PubMed] [Google Scholar]
  28. Xu K, Wu ZJ, Groner AC, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 2012 ; 338 : 1465–1469. [Google Scholar]
  29. Yan J, Li B, Lin B, et al. EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma. Blood 2016 ; 128 : 948–958. [Google Scholar]
  30. Sasaki D, Imaizumi Y, Hasegawa H, et al. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica 2011 ; 96 : 712–719. [CrossRef] [PubMed] [Google Scholar]
  31. Visser HP, Gunster MJ, Kluin-Nelemans HC, et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 2001 ; 112 : 950–958. [PubMed] [Google Scholar]
  32. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010 ; 42 : 181–185. [Google Scholar]
  33. Sneeringer CJ, Scott MP, Kuntz KW, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A 2010 ; 107 : 20980–20985. [CrossRef] [PubMed] [Google Scholar]
  34. Xu F, Li X, Wu L, et al. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol 2011 ; 90 : 643–653. [CrossRef] [PubMed] [Google Scholar]
  35. Völkel P, Dupret B, Le Bourhis X, et al. Diverse involvement of EZH2 in cancer epigenetics. Am J Transl Res 2015 ; 7 : 175–193. [PubMed] [Google Scholar]
  36. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010 ; 42 : 722–726. [Google Scholar]
  37. Nikoloski G, Langemeijer SMC, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010 ; 42 : 665–667. [Google Scholar]
  38. Sashida G, Harada H, Matsui H, et al. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation. Nat Commun 2014 ; 5 : 4177. [PubMed] [Google Scholar]
  39. Momparler RL, Côté S. Targeting of cancer stem cells by inhibitors of DNA and histone methylation. Expert Opin Investig Drugs 2015 ; 24 : 1031–1043. [CrossRef] [PubMed] [Google Scholar]
  40. Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012 ; 8 : 890–896. [PubMed] [Google Scholar]
  41. Mccabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012 ; 492 : 108–112. [CrossRef] [PubMed] [Google Scholar]
  42. Qi W, Chan H, Teng L, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A 2012 ; 109 : 21360–21365. [CrossRef] [PubMed] [Google Scholar]
  43. Kim KH, Kim W, Howard TP, et al. SWI/SNF mutant cancers depend upon catalytic and non–catalytic activity of EZH2. Nat Med 2015 ; 21 : 1491–1496. [CrossRef] [PubMed] [Google Scholar]
  44. Serresi M, Gargiulo G, Proost N, et al. Polycomb repressive complex 2 is a barrier to KRAS-driven inflammation and epithelial-mesenchymal transition in non-small-cell lung cancer. Cancer Cell 2016 ; 29 : 17–31. [CrossRef] [PubMed] [Google Scholar]
  45. Chaib H, Prébet T, Vey N, Collette Y. Histone méthyltransférases : une nouvelle classe de cibles thérapeutiques dans le traitement du cancer ? Med Sci (Paris) 2011 ; 27 : 725–732. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.